Bora Pharmaceuticals Co., Ltd. is intensifying its presence in the rare disease treatment market by acquiring U.S.-based Pyros Pharmaceuticals, a company focused on specialized rare disease therapies. This acquisition, recently approved by Bora’s board of directors, positions Bora Pharmaceuticals to become a leader in addressing rare but critical medical conditions. Pyros Pharmaceuticals, co-founded by Michael […]
Lupin Inc., a wholly-owned subsidiary of the global pharmaceutical major Lupin Limited, announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Chlorpromazine Hydrochloride Tablets USP in various strengths. The approval permits the New Jersey-based company to market a generic equivalent to […]
Upsher-Smith Laboratories has launched three new products – Fluvoxamine Maleate Tablets, Clonidine Hydrochloride Extended-Release Tablets, and Haloperidol Tablets, USP, to expand its generic portfolio. According to the US pharma company, the market for the three generic drugs had combined sales of around $102.5 million in the US for the 12 months ending December 2019, as […]
